Related Experiment Video

Updated: Jul 3, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report

Anne-Mette A Konradsen1, Eva S Petersson1, Morten Grauslund1

  • 1Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Clinical Lung Cancer
|March 28, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CrizotinibEntrectinibNGSPulmonary Squamous Cell Carcinoma

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Experiment Videos

Last Updated: Jul 3, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs.

International journal of molecular sciences·2026

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands)·2026

Survival and relapse of Danish patients with thymic epithelial tumors.

Acta oncologica (Stockholm, Sweden)·2026

Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids.

Frontiers in bioengineering and biotechnology·2026

Deep Learning-Based Tumor Cell Classification in Lung Adenocarcinoma With a Case-by-Case Human-in-the-Loop Approach.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026

Rationale and Design of the MIA Trial: A Proof-of-Concept Study of Minimally Invasive Autopsy in an Infectious Cause of Death in a Scandinavian ICU Setting.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026

PINPOINT: Integrating Computer Assisted Detection and Virtual Nodule Clinics for Early Lung Cancer Detection in Routine Practice, A Pilot Study.

Clinical lung cancer·2026

Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).

Clinical lung cancer·2026

Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center.

Clinical lung cancer·2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Clinical lung cancer·2026

Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review.

Clinical lung cancer·2026

Consolidative Hypofractionated Radiotherapy for Oligometastatic Non-Small-Cell Lung Cancer.

Clinical lung cancer·2026

SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB NSCLC.

JTO clinical and research reports·2026

A Novel Preclinical Mouse Model of Voluntary Active Stretching Suppresses Mammary Tumor Progression.

Medicine and science in sports and exercise·2026

[A Case of Pembrolizumab-Associated Fulminant Type One Diabetes Mellitus during Neoadjuvant Chemotherapy for Early-Stage Breast Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

[A Case of Giant Exophytic Gastric GIST Presenting with the Torricelli-Bernoulli Sign during Regorafenib Treatment].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cance].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

[Perioperative Immunotherapy as a Strategy to Overcome Hepatocellular Carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us